Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2008 1
2009 1
2010 2
2011 2
2013 1
2014 1
2015 2
2016 4
2017 4
2018 10
2019 8
2020 16
2021 13
2022 15
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
Median progression-free survival by blinded independent central review was 17.8 months (95% CI 14.3-20.8) in the trastuzumab deruxtecan group versus 6.9 months (5.5-8.4) in the treatment of physician's choice group (HR 0.36 [0.28-0.45]; p<0.0001). The most common treatm …
Median progression-free survival by blinded independent central review was 17.8 months (95% CI 14.3-20.8) in the trastuzumab deruxtecan grou …
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
Median follow-up was 2.7 years (IQR 1.8-3.6). 336 primary endpoints (22.4 per 100 patient-years) occurred in the ferric derisomaltose group and 411 (27.5 per 100 patient-years) occurred in the usual care group (rate ratio [RR] 0.82 [95% CI 0.66 to 1.02]; p=0.070). In the C …
Median follow-up was 2.7 years (IQR 1.8-3.6). 336 primary endpoints (22.4 per 100 patient-years) occurred in the ferric derisomaltose group …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries.
Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, Batini C, Fawcett KA, Song K, Sakornsakolpat P, Li X, Boxall R, Reeve NF, Obeidat M, Zhao JH, Wielscher M, Weiss S, Kentistou KA, Cook JP, Sun BB, Zhou J, Hui J, Karrasch S, Imboden M, Harris SE, Marten J, Enroth S, Kerr SM, Surakka I, Vitart V, Lehtimäki T, Allen RJ, Bakke PS, Beaty TH, Bleecker ER, Bossé Y, Brandsma CA, Chen Z, Crapo JD, Danesh J, DeMeo DL, Dudbridge F, Ewert R, Gieger C, Gulsvik A, Hansell AL, Hao K, Hoffman JD, Hokanson JE, Homuth G, Joshi PK, Joubert P, Langenberg C, Li X, Li L, Lin K, Lind L, Locantore N, Luan J, Mahajan A, Maranville JC, Murray A, Nickle DC, Packer R, Parker MM, Paynton ML, Porteous DJ, Prokopenko D, Qiao D, Rawal R, Runz H, Sayers I, Sin DD, Smith BH, Soler Artigas M, Sparrow D, Tal-Singer R, Timmers PRHJ, Van den Berge M, Whittaker JC, Woodruff PG, Yerges-Armstrong LM, Troyanskaya OG, Raitakari OT, Kähönen M, Polašek O, Gyllensten U, Rudan I, Deary IJ, Probst-Hensch NM, Schulz H, James AL, Wilson JF, Stubbe B, Zeggini E, Jarvelin MR, Wareham N, Silverman EK, Hayward C, Morris AP, Butterworth AS, Scott RA, Walters RG, Meyers DA, Cho MH, Strachan DP, Hall IP, Tobin M… See abstract for full author list ➔ Shrine N, et al. Nat Genet. 2019 Mar;51(3):481-493. doi: 10.1038/s41588-018-0321-7. Epub 2019 Feb 25. Nat Genet. 2019. PMID: 30804560 Free PMC article.
Genome-wide Association Study for AKI.
Bhatraju PK, Stanaway IB, Palmer MR, Menon R, Schaub JA, Menez S, Srivastava A, Wilson FP, Kiryluk K, Palevsky PM, Naik AS, Sakr SS, Jarvik GP, Parikh CR, Ware LB, Ikizler TA, Siew ED, Chinchilli VM, Coca SG, Garg AX, Go AS, Kaufman JS, Kimmel PL, Himmelfarb J, Wurfel MM. Bhatraju PK, et al. Kidney360. 2023 Jul 1;4(7):870-880. doi: 10.34067/KID.0000000000000175. Epub 2023 Jun 5. Kidney360. 2023. PMID: 37273234 Free PMC article.

RESULTS: No genome-wide significant associations with AKI risk were found in Assessment, Serial Evaluation, and Subsequent Sequelae of AKI (P < 510(8)). The top two variants with the strongest association with AKI mapped to the dispatched resistance-nodulation-division

…
RESULTS: No genome-wide significant associations with AKI risk were found in Assessment, Serial Evaluation, and Subsequent Sequelae of AKI ( …
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, Rodder S, Pandey A, Joshi PH. Neeland IJ, et al. Lancet Diabetes Endocrinol. 2021 Sep;9(9):595-605. doi: 10.1016/S2213-8587(21)00179-0. Epub 2021 Aug 3. Lancet Diabetes Endocrinol. 2021. PMID: 34358471 Clinical Trial.
Mean change in VAT over median 36.2 weeks was -12.49% (SD 9.3%) with liraglutide compared with -1.63% (SD 12.3%) with placebo, estimated treatment difference -10.86% (95% CI -6.97 to -14.75, p<0.0001). Effects seemed consistent across subgroups of age, sex, race-ethnici …
Mean change in VAT over median 36.2 weeks was -12.49% (SD 9.3%) with liraglutide compared with -1.63% (SD 12.3%) with placebo, estimated tre …
Understanding AAV vector immunogenicity: from particle to patient.
Dhungel BP, Winburn I, Pereira CDF, Huang K, Chhabra A, Rasko JEJ. Dhungel BP, et al. Theranostics. 2024 Jan 20;14(3):1260-1288. doi: 10.7150/thno.89380. eCollection 2024. Theranostics. 2024. PMID: 38323309 Free PMC article. Review.
Yoga for the Management of Cancer Treatment-Related Toxicities.
Lin PJ, Peppone LJ, Janelsins MC, Mohile SG, Kamen CS, Kleckner IR, Fung C, Asare M, Cole CL, Culakova E, Mustian KM. Lin PJ, et al. Curr Oncol Rep. 2018 Feb 1;20(1):5. doi: 10.1007/s11912-018-0657-2. Curr Oncol Rep. 2018. PMID: 29388071 Free PMC article. Review.
85 results